CLINICAL TRIALS PROFILE FOR AYGESTIN
✉ Email this page to a colleague
All Clinical Trials for AYGESTIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00474851 ↗ | The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial | Completed | Brigham and Women's Hospital | Phase 2 | 2007-08-01 | The purpose of this study is to determine whether a regimen of norethindrone acetate + placebo or norethindrone acetate + conjugated estrogens is superior in maintaining skeletal health and quality of life in adolescents treated with a GnRH agonist for endometriosis. |
| NCT00474851 ↗ | The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial | Completed | Boston Children's Hospital | Phase 2 | 2007-08-01 | The purpose of this study is to determine whether a regimen of norethindrone acetate + placebo or norethindrone acetate + conjugated estrogens is superior in maintaining skeletal health and quality of life in adolescents treated with a GnRH agonist for endometriosis. |
| NCT00474851 ↗ | The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial | Completed | Boston Children’s Hospital | Phase 2 | 2007-08-01 | The purpose of this study is to determine whether a regimen of norethindrone acetate + placebo or norethindrone acetate + conjugated estrogens is superior in maintaining skeletal health and quality of life in adolescents treated with a GnRH agonist for endometriosis. |
| NCT01391052 ↗ | Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding | Unknown status | Scott and White Hospital & Clinic | Phase 4 | 2011-01-01 | Problematic uterine bleeding after the insertion of the LNG IUS is a well documented side effect. The levonorgestrel intrauterine system (LNG IUS) was approved for treatment of heavy menstrual bleeding (HMB) by the FDA in October 2009. To reduce the incidence and severity of post-insertional uterine bleeding, pretreatment with norethindrone acetate may effectively slough the endometrium prior to insertion of the LNG IUS. |
| NCT02353247 ↗ | Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant | Unknown status | Norton Healthcare | N/A | 2015-08-01 | The overall objective of this study is to confirm that oral progesterone is an effective way to manage bothersome bleeding; thus increasing the rate of continuation of the etonogestrel contraceptive implant in adolescents. |
| NCT02542410 ↗ | Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study | Completed | Boston Children's Hospital | Phase 2 | 2016-05-01 | The proposed pilot study will estimate the efficacy and safety of a novel therapeutic agent, cabergoline, with a clinical standard therapy, norethindrone acetate, for the treatment of endometriosis-associated pain in young women with endometriosis. |
| NCT02542410 ↗ | Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study | Completed | Boston Children’s Hospital | Phase 2 | 2016-05-01 | The proposed pilot study will estimate the efficacy and safety of a novel therapeutic agent, cabergoline, with a clinical standard therapy, norethindrone acetate, for the treatment of endometriosis-associated pain in young women with endometriosis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AYGESTIN
Condition Name
Clinical Trial Locations for AYGESTIN
Trials by Country
Clinical Trial Progress for AYGESTIN
Clinical Trial Phase
Clinical Trial Sponsors for AYGESTIN
Sponsor Name
